Insider filings made public on Wednesday reveal a cluster of significant purchases and disposals by company executives and major holders across multiple sectors, from mining and biotech to financials and cloud infrastructure. The transactions, disclosed in Form 4 filings and similar reports, ranged from small footprints executed through retirement plans to multiday sales under Rule 10b5-1 plans worth tens of millions of dollars.
Top insider buys
IperionX Ltd - Executive chair boosts stake
Todd Hannigan, Executive Chairman of IperionX Ltd, made two sequential purchases of ordinary shares on the Australian Stock Exchange that together totaled roughly A$2,077,784. On April 28, 2026 he acquired 220,000 ordinary shares at an average price of A$4.4819 per share. He followed up on April 29, 2026 with an additional 260,000 shares purchased at an average price of A$4.1991 per share.
Those transactions increased Mr. Hannigan's direct holdings to 26,108,334 ordinary shares. The insider buying occurs against a backdrop in which IPX shares have fallen 34% over the past six months but remain up 32% over the last year. The company currently trades at $29.05 and carries an approximate market capitalization of $1 billion. Analysts collectively hold a strong buy consensus on the stock, with published price targets spanning from $40 to $71, indicating a wide range of upside expectations.
Zenas BioPharma, Inc. - CEO accumulates shares
Leon O. Moulder Jr., Chief Executive Officer and Director of Zenas BioPharma, disclosed two purchases over April 28 and April 29, 2026 totaling about $1,067,200 in common stock. On April 28 he bought 25,000 shares at a weighted average price of $18.02 per share, with the trade executions ranging from $17.87 to $18.05. The next day he acquired 35,000 shares at a weighted average of $17.62 per share, with prices from $17.56 to $17.67.
The filings note these purchases amid a recent pullback in the share price, which declined 12.5% over the past week even as the stock remains 57% higher over the previous 12 months.
PIMCO Dynamic Income Strategy Fund - portfolio manager adds to holding
Daniel J. Ivascyn, a portfolio manager and member of the Executive Committee for the PIMCO Dynamic Income Strategy Fund, purchased 28,779 shares of the fund's common stock on April 27, 2026. The block totaled roughly $592,401, with share prices in the trades ranging from $20.57 to $20.60 per share.
After these acquisitions, Mr. Ivascyn directly holds 2,118,504 shares of the fund's common stock, and an additional 79,534 shares are held indirectly in trust. At the time of the filing the fund trades at $20.95. Over the past year the fund has produced a total return of 21% and offers a dividend yield of 21.82%. The filing also notes the fund maintains an excellent financial health score.
Sonoco Products Co - executive purchase via 401(k)
James A. Harrell III, President of Global Industrial Paper Packaging at Sonoco Products Co, is reported to have added to his indirect holdings through a 401(k) plan on April 27, 2026. Mr. Harrell purchased 6,753.3117 shares at an average price of $50.3728 per share, with the individual transactions nearly identical in price (ranging from $50.3726 to $50.3729). The total disclosed cost of the purchase was $340,183.
Following this indirect acquisition, Mr. Harrell's indirect ownership of Sonoco common stock rose to 10,069.6191 shares. He also directly holds 59,956 shares. Sonoco's common stock is trading at $49.90, close to the purchase price. The company has a long record of dividend increases, having raised its payout for 43 consecutive years and currently yielding 4.33%. A Fair Value assessment cited in the filing places the company at $62.61, suggesting an implied undervaluation relative to market price.
Huntington Bancshares Inc - director increases preferred holding
Director James D III Rollins increased his exposure to Huntington Bancshares Inc preferred securities through purchases made on April 27 and April 28, 2026. The transactions added up to $216,335 in purchases, with prices paid ranging from $17.09 to $21.05 per depositary share. On April 27 Mr. Rollins acquired 6,500 depositary shares that represent interests in the company's 4.50% Series H Non-Cumulative Perpetual Preferred Stock, at a weighted average price of $17.09 and individual trades priced between $17.08 and $17.10.
Top insider sells
CoreWeave, Inc. - major Rule 10b5-1 selling by two executives
CoreWeave reported large, pre-arranged sales executed under Rule 10b5-1 plans by two senior executives on April 27, 2026. Chief Strategy Officer Brian M Venturo sold 375,000 shares of Class A common stock through a plan adopted on November 13, 2025. The sales amounted to roughly $40.9 million at weighted average prices between $105.618 and $112.1407 per share, with individual trade prices spanning $105.02 to $112.76.
On the same date, Chief Development Officer Brannin McBee sold 286,500 shares of Class A common stock under a Rule 10b5-1 trading plan established on November 17, 2025. Those transactions totaled about $31.3 million and occurred at prices ranging from $105.61 to $112.18 per share. Of Mr. McBee's total, 199,000 shares were sold directly by him, 33,350 shares were sold indirectly by his spouse, and 54,150 shares were sold indirectly by the Brannin J. McBee 2022 Irrevocable Trust, for which his spouse serves as trustee and his spouse and minor child are beneficiaries.
CoreWeave shares are currently trading at $114.21, above the weighted average sale prices disclosed by both executives. The company has delivered a significant 176% return over the past year, though it has eased roughly 3% in the prior week. CoreWeave reported 168% revenue growth over the last twelve months through Q4 2025 but remains unprofitable on an EPS basis, with earnings per share of -$2.81. The company carries an approximate market capitalization of $57.3 billion. Note that CoreWeave has an earnings release scheduled for May 7, seven days after the reported insider trades.
Kinetik Holdings Inc - large block sold by ISQ-affiliated entities
ISQ Global Fund II GP LLC, I Squared Capital, LLC, ISQ Holdings, LLC, Sadek Wahba, and Gautam Bhandari - collectively described as 10% owners and referred to in filings as ISQ-affiliated entities - reported sales of 376,343 shares of Class A common stock between April 27 and April 29, 2026. The transactions were valued at approximately $18,451,282, with prices per share ranging from $48.0099 to $49.526.
The securities are reported as being indirectly held by Buzzard Midstream LLC, where ISQ Global Fund II GP, LLC serves as the general partner and exerts voting and investment power. I Squared Capital, LLC is the sole member of Fund II GP, and ISQ Holdings, LLC is listed as the managing member of I Squared Capital. Filings indicate Sadek Wahba and Gautam Bhandari are members of ISQ Holdings, and they disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. Kinetik shares are trading near a 52-week high of $49.73, with a strong year-to-date return of nearly 43% noted in the disclosure.
RE/MAX Holdings, Inc. - Magnolia Capital Fund sells amid strong price momentum
Magnolia Capital Fund, LP, together with its general partner The Magnolia Group, LLC and managing member Adam K. Peterson, disclosed sales of RE/MAX Holdings common stock totaling about $14.03 million across three transactions from April 27 to April 29, 2026. The weighted-average prices for these sales ranged from $9.84 to $11.10 per share. Specifically, on April 27 Magnolia Capital Fund disposed of 632,091 shares at a weighted-average price of $9.84 per share, with the individual trades occurring at prices between $9.72 and $10.07.
The timing of these dispositions coincides with a sharp upward move in RE/MAX shares, which surged 66% over the past week and trade near their 52-week high of $11.62. The filing characterizes the stock as currently overvalued on a Fair Value basis.
Mueller Industries Inc. - CEO reduces stake near 52-week high
Christopher Gregory L. (last name indicated as L.) Gregory, Chairman of the Board and Chief Executive Officer of Mueller Industries Inc., sold 103,266 shares of common stock on April 27, 2026. The transactions produced proceeds of approximately $14,177,389, with individual prices ranging from $137.00 to $138.135 per share.
Mueller Industries is trading close to a 52-week high of $139.68 after an 88% gain over the past year. The filing notes the stock appears overvalued relative to Fair Value and that technical indicators such as the Relative Strength Index suggest the shares may be overbought, factors cited in the disclosure as possible considerations for the CEO's decision to reduce his position.
Context and closing observations
These filings provide a snapshot of how insiders and large holders repositioned in late April 2026. The purchases at IperionX, Zenas BioPharma, PIMCO's fund and Sonoco were presented as purchases of confidence or retirement-plan allocations by executives and portfolio managers. Conversely, the sizeable sales at CoreWeave executed under Rule 10b5-1 plans, and the large dispositions at Kinetik, RE/MAX and Mueller often coincide with elevated share prices or proximity to 52-week highs.
Insider purchases are frequently interpreted by market participants as an expression of confidence in a company’s prospects, while sales can reflect a range of motives including portfolio rebalancing, tax planning, liquidity needs, or predefined trading plans. Filings disclose that CoreWeave's sales were organized under Rule 10b5-1 trading plans adopted in November 2025, and the Kinetik and RE/MAX sales were large, multi-day blocks by major holders and funds. Readers should note these filings only document the transactions and the positions held; they do not, in themselves, reveal the full rationale behind each trade.
Summary
Wednesday's filings show heavy insider activity across multiple sectors. Notable buys included a multi-million dollar accumulation by IperionX's Executive Chairman and purchases by Zenas BioPharma's CEO, a PIMCO portfolio manager and a Sonoco executive through a 401(k). Significant sell-side activity featured Rule 10b5-1 sales by CoreWeave executives totaling more than $70 million, and large disposals by ISQ-affiliated holders at Kinetik, Magnolia Capital at RE/MAX, and Mueller's CEO.
Key points
- Director and executive purchases were largest at IperionX and Zenas BioPharma, reflecting individual accumulation totaling several million dollars.
- CoreWeave saw two senior executives sell under Rule 10b5-1 plans on April 27, 2026, together accounting for more than $70 million in proceeds.
- Other large sellers included ISQ-affiliated entities at Kinetik, Magnolia Capital at RE/MAX, and Mueller Industries' CEO, often coinciding with elevated share prices or 52-week highs.
Risks and uncertainties
- Insider sales under Rule 10b5-1 plans do not disclose the underlying rationale and can occur even as a company’s shares continue to rise, creating ambiguity about management’s view of future performance - relevant to investors in cloud infrastructure and enterprise software names given CoreWeave’s profile.
- High concentrations of sales by major holders or sponsors, such as the ISQ-affiliated entities at Kinetik and Magnolia Capital at RE/MAX, can exert near-term selling pressure when they occur around market highs, affecting midstream and franchising sector liquidity and pricing.
- Insider purchases, while commonly treated as a positive signal, may be executed for a variety of personal or plan-related reasons and should be interpreted alongside broader fundamentals; investors in resource and biotech sectors may find these transactions informative but not dispositive.
Monitoring insider trading disclosures provides an additional datapoint for investors assessing corporate leadership alignment with shareholders. These filings should be used together with fundamental analysis, valuation metrics and an understanding of trading-plan mechanics before forming an investment view.